Implantable non-enzymatic electrochemical glucose sensor

• US 5,469,846 A
• Filed: 09/27/1994
• Issued: 11/28/1995
• Est. Priority Date: 10/19/1992
• Status: Expired due to Fees

• Current Assignee: Duquesne University of The Holy Ghost
• Original Assignee: Duquesne University of The Holy Ghost
• Inventors: Khan, Shahed U. M.
• Primary Examiner(s): Sykes, Angela D.
• Assistant Examiner(s): WINAKUR, ERIC FRANK
• Application Number:
  US08/312,891
• Time in Patent Office: 427 Days
• Field of Search: 128/635, 128/632, 604/31, 604/891.1, 204/403, 204/415
• US Class Current: 600/347
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1473 invasive, e.g. introduced into the body by a catheter A61B5/1482 takes precedence
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00

Abstract

A non-enzymatic implantable blood glucose detector. The detector makes use of a non-reactive tin oxide semiconductor measurement electrode which is suitably energized by an electrical power source. Variations in current density at the measurement electrode are related to variations in glucose content of blood. The device also uses variable voltage to allow the electrode to be self-cleaning.

Claims

1. A method of detecting changes in blood glucose levels, comprising:

providing an implantable non-enzymatic blood glucose detector having a non-reactive semiconductor measurement electrode energized by a battery means and disposed within a sleeve member having an opening permitting glucose molecules to pass therethrough to said measurement electrode, but resisting the passage therethrough of molecules of predetermined greater size;

connecting said measurement electrode to a monitoring means for monitoring a current density at said measurement electrode in response to glucose molecule oxidation or glucose molecule reduction reactions at said measurement electrode;

continuously passing blood through said sleeve opening to said measurement electrode;

continuously monitoring said current density by said monitoring means; and

translating changes in current density detected by said monitoring means to changes in blood glucose levels.

2. The method of claim 1 employing as material for said semiconductor measurement electrode a semiconductor selected from the group consisting of tin oxide and titanium dioxide.

3. The method of claim 2 employing said sleeve member opening covered with a biocompatible membrane sized to permit glucose molecules to pass therethrough, but to preclude passage therethrough of molecules sized greater than about 100,000 M.W.

4. The method of claim 1 employing as said sleeve member a venturi sleeve having a restricted opening for allowing said glucose molecules to pass therethrough, but precluding passage therethrough of molecules larger than about 100,000 M.W.

5. The method of claim 1 employing said battery means at a variable voltage, thereby maintaining said measurement electrode in a clean state.

6. A method of delivering insulin within a patient comprising:

providing an implantable non-enzymatic blood glucose unit comprising an implantable non-reactive semiconductor measurement electrode, said electrode energized by an electrical power source and disposed within a sleeve member having an opening permitting glucose molecules to pass therethrough to said measurement electrode, but precluding the passage therethrough of molecules sized greater than about 100,000 M.W., said unit further comprising monitoring means connected to said electrode for monitoring current density at said measurement electrode, said unit further including an insulin reservoir and insulin pump;

implanting said unit in a patient;

continuously passing blood from said patient through said sleeve opening to said measurement electrode;

continuously monitoring changes in current density at said measurement electrode in response to glucose molecule oxidation or glucose molecule reduction reactions at said measurement electrode, with said monitoring means;

translating changes in current density detected by said monitoring means to changes in blood glucose levels; and

delivering insulin from said insulin reservoir to said patient via said insulin pump in response to changes in current density detected by said monitoring means in response to changes in blood glucose levels from a normal glucose level to a glucose level exceeding a predetermined set point.

7. The method of claim 6 employing as said electrical power source a battery means.

8. The method of claim 6 employing as a material for said semiconductor electrode a semiconductor selected from the group consisting of tin oxide and titanium dioxide.

9. The method of claim 8 employing said sleeve member opening covered with a biocompatible membrane sized to permit glucose molecules to pass therethrough, but to preclude passage therethrough of molecules sized greater than about 100,000 M.W.

10. The method of claim 8 employing as said sleeve member a venturi sleeve having a restricted opening for allowing said glucose molecules to pass therethrough, but precluding passage therethrough of molecules sized greater than about 100,000 M.W.

11. The method of claim 6 employing said electrical power source at a variable voltage, thereby maintaining said measurement electrode in a clean state.

12. The method of claim 6 further employing with said unit a glucose reservoir and glucose pump, said method including the step of delivering glucose to said patient via said glucose pump in response to current density changes detected by said monitoring means corresponding to changes in blood glucose levels from a normal glucose level to a glucose level below a predetermined set point.